Who Supplies Dapagliflozin to India from URUGUAY

To import finished pharmaceutical formulations containing Dapagliflozin (HS Code 30049099) into India, the Central Drugs Standard Control Organization (CDSCO) mandates that both the foreign manufacturer and the Indian importer obtain specific approvals. The foreign manufacturer must secure a Certificate of Pharmaceutical Product (CoPP) from the regulatory authority in Uruguay, confirming compliance with Good Manufacturing Practices (GMP). The Indian importer is required to obtain an Import License from the Directorate General of Foreign Trade (DGFT) and register the product with CDSCO. The registration process involves submitting Form 40/41, which includes detailed product information, manufacturing licenses, and GMP certificates. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory processing times. It's essential to ensure that all documentation is accurate and complete to avoid delays.

Upon arrival in India, each batch of Dapagliflozin formulations must undergo quality testing at a CDSCO-approved laboratory. The importer is responsible for providing a Certificate of Analysis (CoA) for each batch, demonstrating compliance with the Indian Pharmacopoeia standards. Stability data, particularly for ICH Zone IV conditions, should be included to confirm the product's shelf-life under Indian climatic conditions. Customs drug inspectors conduct port inspections to verify the authenticity of the CoA and may collect samples for independent testing. If a batch fails to meet the required standards, it may be rejected, and the importer could face penalties or be barred from future imports.

Between 2024 and 2026, the CDSCO introduced stricter regulations for importing pharmaceutical products to enhance drug safety and efficacy. Notably, in April 2025, the CDSCO mandated that all imported drugs, including finished formulations, must have prior registration and an import license before distribution in India. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. Additionally, the introduction of the Production Linked Incentive (PLI) scheme in 2024 has encouraged domestic manufacturing, potentially impacting the volume of finished formulation imports. While the PLI scheme primarily targets domestic production, it may influence import dynamics as companies assess the cost-effectiveness of manufacturing locally versus importing.

India's demand for finished Dapagliflozin formulations is driven by the increasing prevalence of Type 2 diabetes and the need for effective glycemic control. While domestic manufacturers produce Dapagliflozin tablets, certain patented or specialized formulations, such as combination drugs, are not available locally. This gap in the domestic market necessitates imports to meet patient needs. The market size for Dapagliflozin formulations in India is substantial, with a growing number of patients requiring treatment. The import dependency is significant for these specialized formulations, highlighting the importance of international trade in fulfilling domestic demand.

The import duty structure for finished pharmaceutical formulations under HS Code 30049099 includes a Basic Customs Duty (BCD) of 10%, an Education Cess of 2%, and a Secondary Higher Education Cess of 1%, totaling 13%. Additionally, a Countervailing Duty (CVD) of 6% is applied, bringing the total duty to 19%. The Social Welfare Surcharge (SWS) is 10%, and the Integrated Goods and Services Tax (IGST) is 12%, resulting in a total landed duty of approximately 41%. These duties are subject to change based on government policies and trade agreements.

Uruguay's pharmaceutical industry is known for producing high-quality finished formulations, including Dapagliflozin tablets. The country's adherence to international GMP standards and the availability of specialized formulations not produced in India make it a competitive source for these products. While other countries like China, Germany, and the United States also export Dapagliflozin formulations to India, Uruguay's focus on quality and specialized products provides a unique advantage. Uruguay's share in the Indian market for Dapagliflozin formulations is growing, reflecting its competitive position.

India imports finished Dapagliflozin formulations from Uruguay due to the availability of specialized combination drugs not produced domestically. Uruguay's pharmaceutical industry adheres to international GMP standards, ensuring high-quality products. The country's focus on innovation and quality in pharmaceutical manufacturing makes it a reliable source for these formulations.

Compared to other sources like China, the European Union, and the United States, Uruguay offers competitive pricing and high-quality products. While China may offer lower prices, concerns about quality